



- (51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/06* (2006.01)
- (21) International Application Number:
PCT/US2016/052040
- (22) International Filing Date:
16 September 2016 (16.09.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/220,442 18 September 2015 (18.09.2015) US
- (71) Applicant: **CEPHALON, INC.** [US/US]; 41 Moores Road, Frazer, PA 19355 (US).
- (72) Inventors: **POULTON, Lynn, Dorothy**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **POLLARD, Matthew**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **DOYLE, Anthony, G.**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **COOKSEY, Bridget, Ann**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **PANDE, Vanya**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **CLARKE, Adam, William**; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU).
- (74) Agents: **COCCA, Brian, A.** et al.; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, PA 19355 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES THAT SPECIFICALLY BIND TO TL1A

(57) Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

